Retina

The purpose of the study was to determine if experience affects the surgeons’ dexterity response to pharmacologic and behavioral interventions.

Novice surgeons affected more than seasoned surgeons

Theodore Leng, MD, MS, speaks about his ASRS presentation, focusing on the FARETINA-DME Study

Ahead of the ASRS meeting, Rishi P. Singh, MD, previews results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for geographic atrophy

Carl C. Awh, MD, FASRS, gives an overview of the Phase 3 Pagoda trial year 2 results

Martin Zinkernagel, MD, PhD, sat down with Hattie Hayes, Editor of Ophthalmology Times Europe, to discuss his time on the sustainability expert panel Study at the American Society of Retina Specialists meeting held in Stockholm, Sweden.

Carl J. Danzig, MD, discusses efficacy, safety, and durability of faricimab in macular oedema due to retinal vein occlusion

This year, the ASRS meeting will feature an expert panel on sustainability — learn more from panelist Martin Zinkernagel, MD, PhD

Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal geographic atrophy

Four retina specialists share what they're most looking forward to at the 2024 ASRS meeting

Jennifer I. Lim, MD, FARVO, FASRS, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss her ASRS 2024 presentation, "Differential Artery-Vein Analysis Improves OCTA Performance for Artificial Intelligence Classification of Diabetic Retinopathy."

Jennifer I. Lim, MD, FARVO, FASRS, discusses her ASRS presentation, "Differential Artery-Vein Analysis Improves OCTA Performance for Artificial Intelligence Classification of Diabetic Retinopathy"

Scientists from the International Centre from Translational Eye Research used multiwavelength laser Doppler holography to assess blood flow in various layers of the human retina in vivo, which may impact the diagnosis of circulatory disorders.

Companies in the retina space announced presentations ahead of the American Society of Retina Specialists meeting, to be held 17-20 July

Researchers, led by Shigemi Matsuyama, PhD, will conduct research seeking a potential breakthrough drug that can be taken orally—one that may address many RP disease manifestations, regardless of the underlying genetic mutation.

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss nonleaking cystoid macular edema and subretinal fluid out of proportion to optic disc edema in idiopathic intracranial hypertension in the setting of optic atrophy.

The companies are teaming up to reduce care gaps and improve eye and vision health by bringing diabetic retinopathy and other eye disease screening services to patients in their own homes and workplaces.

The company has secured $170 million (approximately €157 million) in Series B funding

The funding will go toward the continued clinical development of the company’s lead asset, AGTC-501 (laruparetigene zovaparvovec)

Extended daylight hours and plentiful outdoor space make Stockholm a memorable destination for meeting attendees

The deal included a total upfront consideration of $81 million, including a cash payment of approximately $65 million.

Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea

Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular oedema

The drug is a biosimilar for aflibercept 2 mg (Eylea)